21437-82-1

Basic information

• Product Name: 3-BROMO-N-(4-METHYLPHENYL)PROPANAMIDE
• Synonyms: 3-BROMO-N-(4-METHYLPHENYL)PROPANAMIDE;3-bromo-N-(4-methylphenyl)propionamide;NSC98133
• CAS NO: 21437-82-1
• Molecular Formula: C₁₀H₁₂BrNO
• Molecular Weight: 242.11
• Mol File: 21437-82-1.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 377.5°Cat760mmHg
• Flash Point: 182.1°C
• Appearance: /
• Density: 1.437g/cm³
• Vapor Pressure: 6.71E-06mmHg at 25°C
• Refractive Index: 1.6
• CAS DataBase Reference: 3-BROMO-N-(4-METHYLPHENYL)PROPANAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-BROMO-N-(4-METHYLPHENYL)PROPANAMIDE(21437-82-1)
• EPA Substance Registry System: 3-BROMO-N-(4-METHYLPHENYL)PROPANAMIDE(21437-82-1)

Safety Data

• Hazardous Substances Data: 21437-82-1(Hazardous Substances Data)

Usage

InChI:InChI=1/C10H12BrNO/c1-8-2-4-9(5-3-8)12-10(13)6-7-11/h2-5H,6-7H2,1H3,(H,12,13)

Upstream product

• 106-49-0 p-toluidine 
• 15486-96-1 3-Bromopropionyl chloride 

Downstream Products

• 38560-27-9 N-(4-methylphenyl)azetidin-2-one 
• 191168-82-8 3-Piperazin-1-yl-N-p-tolyl-propionamide 
• 1235866-20-2 9-O-[(3-oxo-3-p-tolylamino)propyl]berberine bromide 
• 36054-00-9 6-methyl-2,3-dihydroquinolin-4(1H)-one 
• 1385731-24-7 2-methyl-10-phenylacridin-9(10H)-one 

Relevant articles and documents

Asymmetric Synthesis and in Vitro and in Vivo Activity of Tetrahydroquinolines Featuring a Diverse Set of Polar Substitutions at the 6 Position as Mixed-Efficacy μ Opioid Receptor/δ Opioid Receptor Ligands

We previously reported a small series of mixed-efficacy μ opioid receptor (MOR) agonist/δ opioid receptor (DOR) antagonist peptidomimetics featuring a tetrahydroquinoline scaffold and showed the promise of this series as effective analgesics after intrape

Peptidomimetics and Methods of Using the Same

Disclosed herein are compounds useful for modulating the mu-opioid receptor (“MOR”) and/or delta-opioid receptor (“DOR”), and methods of using these compounds to treat diseases and conditions, such as pain. In particular, disclosed herein are compounds of

Synthesis, in vitro and in silico studies of novel potent urease inhibitors: N-[4-({5-[(3-Un/substituted-anilino-3-oxopropyl)sulfanyl]-1,3,4-oxadiazol-2-yl}methyl)-1,3-thiazol-2-yl]benzamides

The present article describes the synthesis, in vitro urease inhibition and in silico molecular docking studies of a novel series of bi-heterocyclic bi-amides. The synthesis of title compounds was initiated by benzoylation, with benzoyl chloride (1), of the key starter ethyl 2-(2-amino-1,3-thiazol-4-yl)acetate (2) in weak basic aqueous medium followed by hydrazide formation, 4, and cyclization with CS2 to reach the parent bi-heterocyclic nucleophile, N-{4-[(5-sulfanyl-1,3,4-oxadiazol-2-yl)methyl]-1,3-thiazol-2-yl}benzamide (5). Various electrophiles, 8a–l, were synthesized by a two-step process and these were finally coupled with 5 to yield the targeted bi-heterocyclic bi-amide molecules, 9a–l. The structures of the newly synthesized products were corroborated by IR, 1H NMR, 13C NMR, EI-MS and elemental analysis. The in vitro screening of these molecules against urease explored that most of the compounds exhibit potent inhibitory potential against this enzyme. The compound 9j, with IC50 value of 2.58 ± 0.02 μM, exhibited most promising inhibitory activity among the series, relative to standard thiourea having IC50 value of 21.11 ± 0.12 μM. In silico studies fully augmented the experimental enzyme inhibition results. Chemo-informatics analysis showed that synthesized compounds (9a–l) mostly obeyed the Lipinski's rule. Molecular docking study suggested that ligand 9j exhibited good binding energy value (?7.10 kcal/mol) and binds within the active region of target protein. So, on the basis of present investigation, it was inferred that 9j may serve as a novel scaffold for designing more potent urease inhibitors.